
COPD
Latest News
Latest Videos

CME Content
More News

FDA approval expands Breztri Aerosphere from COPD to asthma, offering single-inhaler triple therapy for adults and pediatric patients 12+.

Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.

Astegolimab shows promise in reducing chronic obstructive pulmonary disease (COPD) exacerbations, offering hope for improved management of this debilitating lung disease.

Even patients who are confident in their abilities often use incorrect technique

Pharmacists have the skills to improve patient outcomes and relieve burdens on other providers.

Mepolizumab gains FDA approval as a promising add-on therapy for COPD patients with eosinophilic phenotype, reducing exacerbation rates significantly.

Adults with asthma or COPD face a heightened risk of RSV-related illness.

High-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B did not have significant correlations with chronic obstructive pulmonary disease.

The authors found that humidity, cold and heat waves, and air pollution led to a higher likelihood of asthma- and chronic obstructive pulmonary disease (COPD)-related hospitalizations.


Compared prednisolone alone, benralizumab with and without prednisolone resulted in fewer treatment failures and stronger VAS scores.

During a 15-year period, 1 in 5 older adults living with COPD received a shingles vaccine.

In the analysis, 34.7% of commercially insured patients with chronic obstructive pulmonary disease or asthma received an influenza vaccination.

FDA Approves Dupilumab as Add-On Maintenance Therapy For Adults With COPD
Dupilumab is the first biologic medicine for patients with chronic obstructive pulmonary disease to be approved in the US.

The exhaled breath condensate mask was able to successfully monitor and accurately detect breath for nitrate in patients with asthma or chronic obstructive pulmonary disease.

As dupilumab garners positive clinical trial results in patients with chronic obstructive pulmonary disease, it is increasingly important that pharmacists educate themselves on the treatment.

After over 2 decades, the first inhaled product with a novel mechanism of action has been approved by the FDA for the treatment of chronic obtrusive pulmonary disorder.




















































































































